Search results
May 10, 2024 · There is a growing public health need for effective preventive interventions against dengue, a disease caused by four viruses, termed serotypes 1–4. Two dengue vaccines have been licensed, Dengvaxia® (CYD-TDV), developed by Sanofi Pasteur, and Qdenga® (TAK-003), developed by Takeda.
May 15, 2024 · Earlier this year, WHO listed dengue as a potential threat among ten diseases for 2019 and current outbreaks in many countries confirm this observation. Dengue epidemics tend to have seasonal patterns, with transmission often peaking during and after rainy seasons.
May 14, 2024 · People can be infected with dengue multiple times. For people who have not had dengue before, the vaccine can increase the risk of severe infection. Learn how dengue vaccine eligibility relates to previous infection and when vaccination is recommended.
May 14, 2024 · Dengvaxia is the only dengue vaccine approved by the U.S. Food and Drug Administration and recommended for routine use by the Advisory Committee on Immunization Practices. It is made by Sanofi Pasteur. The vaccine prevents dengue caused by all four dengue virus serotypes.
5 days ago · WHO has published an updated guideline for infection prevention and control in the context of covid-19. In the healthcare facility, WHO recommends consistent application of standard and transmission based precautions to prevent SARS-CoV-2 transmission.
May 2, 2024 · Data on dengue cases with serotype information available were obtained from the Nicaraguan Dengue Surveillance Program; many more cases were confirmed via serology that are not included here because the serotype is unknown.
